Skip to main content
PTGX logo

PTGX · Protagonist Therapeutics, Inc

Track PTGX — free
$127.16 +2.49 (+2.00%) At close · Nov 18
Market Cap
$8.30B
Shares
65.27M
Volume · Nov 18 433.18K Avg daily vol (3M) 666.83K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$127.16 Open$124.54 Day$124.11–127.80 52W close$79.73–158.62 Avg vol 30d657K Short int10.2M · 15.7% of shares · 16.9d Short vol62% Last earningsAug 5, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 6

Up next

Mar 22, 2027 Est · unconfirmed · in 18 wks
call held Mar 10, 2021

Latest documents

2026
Nov 17
Investor event
Icotide Tops 20,000 Prescriptions; Sales Breakdown Expected in 2027

Protagonist's CEO said J&J reported more than 20,000 prescriptions for Icotide, and that J&J guided toward breaking out its sales as a line item sometime in 2027. He also said over half a billion of milestones are pending. A decision on a second indication for the oral candidate is planned for the second half of next year, assuming enrollment proceeds at a decent pace.

6 source passages
the launch is like almost at an unprecedented scale of more than 20,000 prescriptions already as reported by J&J during their earnings call. I believe during their earnings call, they guided towards breaking it down as a line item sometime in 2027. until Icotide got fully secured going into phase three, the research component was still going on. we do have a good chunk of over half a billion of milestones also that are pending. we will just, in the second half of next year, assuming the enrollment is going at a decent pace, make a judgment call on the second indication. And at Protagonist, at least, we derive a big differentiation between what is it that we can do versus what is it that we truly choose to do. Open the document at this passage
Nov 6
Quarterly report 10-Q FY2026 Q3, ended Sep 30
MIMRYLO payments drive $220,015 thousand quarterly profit

Protagonist Therapeutics, Inc. reported net income of $220,015 thousand for the three months ended September 30, 2026, driven by $274.4 million in collaboration revenue following MIMRYLO approval and Takeda opt-out payments; cash and marketable securities reached approximately $834.6 million.

Revenue $274.41M ▲ 5723.6% Net income $220.02M Diluted EPS $3.07
Read from the MD&A section
5 source passages
“Protagonist,” the Protagonist logo and other trademarks, service marks and trade names of Protagonist Therapeutics, Inc. in the United States and other jurisdictions. For the three months ended September 30, 2026, we recognized license and collaboration revenue of $274.4 million. This revenue was primarily driven by the proportional recognition of $266.6 million related to the $275.0 million in total opt-out and milestone payments earned under the Takeda Collaboration Agreement during the period, ongoing development services, and other revenues. MIMRYLO™ (rusfertide), a subcutaneously delivered first-in-class hepcidin mimetic, was approved in the United States in August 2026 for the treatment of erythrocytosis in adults with the rare blood disorder polycythemia vera (“PV”). Net income (loss) | | $ | 220,015 | | $ | (39,339) | | $ | 259,354 | | * We ended the third quarter of 2026 with cash, cash equivalents and marketable securities of approximately $834.6 million, as compared to cash, cash equivalents and marketable securities of approximately $646.0 million as of December 31, 2025. Open the document at this passage
Nov 5
Current report 8-K
MIMRYLO Approval Triggered $275 Million in Payments

Protagonist Therapeutics reported that MIMRYLO’s FDA approval triggered $275 million in payments, third-quarter net income was $220.0 million, and the Board authorized a $300 million share repurchase program.

Financial results
4 source passages
Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist” or “the Company”) today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update. The FDA approval of MIMRYLO triggered $275 million in payments to Protagonist, consisting of a $200 million opt-out payment and a $75 million approval milestone. Net income was $220.0 million, or $3.32 per basic share and $3.07 per diluted share, for the third quarter of 2026 as compared to net loss of $39.3 million, or $0.62 per basic and diluted share, for the third quarter of 2025. On September 8, Protagonist announced that its Board of Directors authorized a share repurchase program under which the Company may repurchase up to $300 million of its outstanding common stock. Open the document at this passage
Aug 5
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $213.48M ▲ 3749.2% Net income $162.85M Diluted EPS $2.29
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$551.69M
Trailing 12 months
Net income (TTM)
$342.26M
Trailing 12 months
Revenue growth YoY
+5,723.6%
Year over year
Operating margin
58.6%
Trailing 12 months
P / E (TTM)
26.9
Trailing earnings · reciprocal yield 3.7%
FCF yield
1.3%
TTM · current market cap
Return on invested capital
110.8%
Trailing 12 months
Net cash
$800.06M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+12.5%
Year over year · more shares
Price change (1Y)
+50.7%
Trailing year
Short interest
15.7%
Latest settlement · 16.9 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Strong Sentiment Bullish Fundamentals Strong Quant / Vol High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg +6%
above
Price vs 50-day avg −9%
below
RSI (14) 37
neutral
MACD trend Negative
52-week position 60%
mid-range
Momentum
relative strength
Strong
1-month return −8%
trailing
6-month return +28%
trailing
YTD return +46%
this year
Relative strength +31%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $139 › 200d $120 — 50d above 200d
Institutional flow Accumulating
+10% holders QoQ · +77 funds added
Insider flow Distributing
Net -$338.8K over 90 days · 100% sells
Short interest Falling
15.69% of shares out · ▼ -0.5% MoM · 16.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
382 holders — near 3-yr high, broad support
Squeeze score 69
elevated · 0–100
Fundamentals
Strong
Revenue growth −89%
Y/Y
EPS growth −148%
Y/Y
Free cash flow $56.1M
Valuation P/E 26.9
below peers
Buyback $294.2M
remaining
Balance sheet $128.4M
net cash
Quant / Vol
risk profile
High
Volatility 40%
annualized · 1-yr
Max drawdown −21%
past year
ATR 4.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Nov 5, 2026
Share repurchases · authorized on September 8, 2026 (no specific period stated) up to $300M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+6% Bullish
Price vs 50-day avg
−9% Bearish
RSI (14)
37 Neutral
MACD trend
Negative Bearish
52-week position
60% Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $139 › 200d $120 — 50d above 200d
Institutional flow Accumulating
+10% holders QoQ · +77 funds added
Insider flow Distributing
Net -$338.8K over 90 days · 100% sells
Short interest Falling
15.69% of shares out · ▼ -0.5% MoM · 16.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
382 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $80 Now $127 · 60% Range high $159
vs 200-day avg +6% vs 50-day avg -9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PTGX
Protagonist Therapeutics, Inc
this stock
$8.30B +45.6% -89.4% 26.9 15.7%
VRTX
Vertex Pharmaceuticals Inc
$136.01B +18.3% +46.2% 34.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$97.81B +22.5% +20.8% 20.9 2.1%
MRNA
Moderna, Inc.
$79.63B +567.3% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
382
% held
118.4%
Net QoQ
+1.5M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
413
View
Short & Settlement
Short Interest Falling
Shares short
10.2M
Days to cover
16.9d
Change
-54.9K sh
View
Short Volume
Short vol %
62%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
1.3K
Value
$177.6K
As of
Oct 6, 2026
View
Off-Exchange
Off-exchange %
41.5%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$338.8K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-130.1M
EPS diluted
$-2.05
View
Buybacks
Authorized
$300.0M
Remaining
$294.2M
Spent Remaining
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 17, 2026
This year
16

Protagonist's CEO said J&J reported more than 20,000 prescriptions for Icotide, and that J&J guided toward breaking out its sales as a line item sometime in 2027. He also said over half a billion of milestones are pending. A decision on a second indication for the oral candidate is planned for the second half of next year, assuming enrollment proceeds at a decent pace.

View
Proposed Sales
Value
$338.8K
Shares
2.7K
Filed
Nov 17, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 17, 2026
View
Investor Relations
Latest news
Protagonist Reports Third Quarter…
Published
Nov 5, 2026
View

Performance

5D 20D 120D MTD YTD
PTGX -5.7% -7.9% +27.7% -12.2% +45.6%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY -1.8% -2.4% +31.2% -8.8% +38.5%

Capital returns

Buyback program · as of Sep 30, 2026
Authorized
$300.00M
Spent (derived)
$5.80M
Remaining
$294.20M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1377121 CUSIP 74366E102 13F (30d) 382 filings 356 filers Visit website Investor relations